Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.63 |
| ▸ | HTR2B | P41595 | 4/20 | 0.63 |
| ▸ | HTR2A | P28223 | 3/20 | 0.63 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.49 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018994 | 1.00 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL23993579 | 1.00 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL20080189 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL17004069 | 0.81 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3SLC6A2 | |
| SCHEMBL16591246 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL22334928 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3SLC6A2 | |
| SCHEMBL16590511 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL21503512 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL6582897 | 0.79 | HTR2C (0.63) | HTR2CHTR2BHTR2ASLC6A3DRD2 | |
| SCHEMBL16477343 | 0.79 | HTR2C (0.66) | HTR2CHTR2BHTR2ASLC6A3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022052886-A1 | CD73 INHIBITOR AND APPLICATION THEREOF IN MEDICINE | 贝达药业股份有限公司 | 2022-03-17 | — | — | WO | disclosed |
| EP-2928457-B1 | CYCLOPROPYLAMINE DERIVATIVES USEFUL AS INHIBITORS OF HISTONE DEMETHYLASES KDM1A | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2020-08-12 | — | — | EP | disclosed |
| US-9738642-B2 | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | BRISTOL MYERS SQUIBB CO (US) | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237081-A1 | TRIAZOLOPYRIDINE ETHER DERIVATIVES AND THEIR USE IN NEUROLOGICAL AND PYSCHIATRIC DISORDERS | GRM2, GRIK2, GRIA2 | HTR2C 34/4885HTR2B 145/4885HTR2A 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.